OBJECTIVES: Concerns have been raised about the durability of the first-generation Mitroflow aortic bioprosthesis (model 12 A-LX) due to the lack of anticalcification treatment. This study reflects a 10-year experience with this prosthesis for aortic valve replacement.
INTRODUCTION
The Mitroflow bioprosthesis (LivaNova Group Inc., Vancouver, Canada) is a widely used substitute, consisting of a glutaraldehydefixed bovine pericardial sheet mounted externally on a semi-flexible polymer-supported frame stent. Since its introduction in 1982, the original model 11 A was redesigned consecutively in model 12 A and model LX but still contained bovine pericardium without antimineralization treatment. In 2011, the third-generation model DL was introduced, including for the first time a phospholipid reduction therapy as an anticalcification treatment. A large number of Mitroflow bioprostheses for aortic valve replacement (AVR) have been implanted worldwide, exhibiting an excellent performance, both in terms of haemodynamic behaviour and in terms of durability over 15 to 20 years, in patients 65 years or older [1, 2] . However, recent reports included concerns about the appearance of early accelerated structural degeneration in patients receiving the non-treated models 12 A and LX [3] [4] [5] . This observation was particularly true for the small sizes 19 and 21, eliciting the call for closed surveillance because of the unpredictable life-threatening impact on patient outcomes [4] . Since Flameng et al. identified a cumulative negative effect on prosthesis longevity for lack of antimineralization treatment and the presence of patient-prosthesis mismatch (PPM), the choice of valve type and size emphasizes the importance of the surgeon's decision at the time of implantation [6] .
Therefore, we decided to review our institutional experience with the use of the Mitroflow bioprosthesis for AVR over the past 10 years, with special focus on the influence of the first-generation models on valve-related outcome and patient survival.
PATIENTS AND METHODS
This retrospective study was approved by the local ethical committee of the Gent University Hospital (B670201525637), waiving the need for informed consent.
Between June 2003 and May 2012, the Mitroflow bioprosthesis model 12 A or LX was used consecutively in 510 patients as the first choice of a biological substitute for AVR. Patient data were retrospectively gathered from medical records. To assess properly the long-term valve outcome, only patients who had complete clinical follow-up data available at the time of study closure were included for analysis, comprising a cohort of 467 patients.
The surgical procedure was routinely performed with standard cardiopulmonary bypass at moderate hypothermia and crystalloid cardioplegic arrest. The aortic valve prosthesis was consistently implanted at the supra-annular level, with single interrupted sutures and avoidance of pledgets, by all surgeons on the team. Proper valve sizing was done with the manufacturer's size obturators, allowing the measurement of the maximally stretched intraannular diameter. Root enlarging procedures were not performed.
PPM was prospectively recorded at the time of the operation, based on the in vivo effective orifice area (EOA) as projected by the manufacturer and normalized to the patient's body surface area [7] . Data on morbidity and mortality are reported in accordance with the guidelines of Akins and co-workers [8] .
The study follow-up was closed in December 2015 and was based on the reports from the last annual visit, including the last echocardiographic examination. The patient's status was defined at that time as alive, dead including the date of death or lost to follow-up. The clinical follow-up was 100% complete, yielding a median follow-up time of 6.6 years [interquartile range (IQR) 4.4-max 11.6 years] and a total of 2375 patient-years. The echocardiographic follow-up was 90% complete, yielding 1536 patient-years (median follow-up 5.4 years (IQR 5.0). Standard parameters were retrieved from the echocardiographic scans obtained at the last follow-up available in late survivors or before repeat surgery or death. Functional assessment of the bioprosthesis was based on the measurement of transvalvular gradients and quantification of prosthetic regurgitation according to the American Society of Echocardiography guidelines [9] .
According to the American Heart Association guidelines on valvular heart diseases, patients with an aortic bioprosthesis were treated with vitamin K antagonists for 3 months after AVR until 2008 and from then on with low-dose aspirin only, except when concomitant diseases required the administration of oral anticoagulants [10, 11] .
Valve-related outcomes included the freedom from thromboembolism, bleeding, endocarditis and structural valve degeneration (SVD). SVD was defined as the intrinsic dysfunction of the prosthesis, necessitating replacement, or echocardiographic dysfunction, determined by a mean transprosthetic gradien >40 mmHg and/or regurgitation >Grade 2. The freedom from valve reoperation was determined by the need for surgical or transcatheter valve replacement. Diagnosis of endocarditis was based on the appearance of a significant paravalvular leak, abscess or vegetation in the presence of clinical and biochemical criteria of systemic infection, according to the Duke criteria [12] .
Statistical analysis
Continuous data are expressed as mean ± standard deviation, or median (IQR), according to the distribution of the data. Categorical variables are shown as number and frequency. Comparison between categorical variables was done by the Fisher's exact test. Operative mortality was defined as 30-day mortality. Multivariable analysis of operative mortality was based on logistic regression analysis, and predictors were given by the odds ratio and 95% confidence interval (CI). Late survival analysis was done with the Kaplan-Meier product-limit estimation method, followed by Cox proportional regression analysis to identify determinants of late survival in a multivariable model. Independent risk factors were reported by the hazard ratio (HR) and 95% CI. Competing risk analysis was performed to assess the valve-related end-points of thromboembolism, bleeding and SVD, with death as a competing risk event, to compute the cumulative incidence function. The FineGray subdistribution hazard model was then applied to estimate the effect of significant determinants of SVD [13] . The level of significance was set at P < 0.05. Statistical data analysis was performed with SPSS version 23.0 (IBM SPSS Statistics, Chicago, IL, USA) and the competing risk analysis software package in R version 3.3.2.
RESULTS

Patient and operation characteristics
Patient and operative data are summarized in Tables 1 and 2 . Patients were on average aged 76.4 ± 6.1 years, presenting predominantly with degenerative aortic valve stenosis (97%). Thirtythree percent (n = 155) were aged less than 75 years at the time of AVR, whereas 22% (n = 103) were older than 80 years. Comorbidities were common in these patients, resulting in a median predicted mortality risk by EuroSCORE II of 3.98% (IQR 4.11).
Concomitant procedures were performed in two-thirds of the patients, with coronary artery bypass surgery (56.3%) being the most frequent. The size distribution of the implanted valves is depicted in Fig. 1 . Sizes 19 to 21 were used in 19.2%, whereas the 
Survival
The overall 30-day mortality was 6.8% (n = 31), but 4.7% (n = 22) for elective patients. Multivariable analysis of risk factors for early death retained preoperative renal failure with the need for dialysis (odds ratio 8.73, 95% CI 1.94-39.29, P = 0.005) and left ventricular ejection fraction <30% (odds ratio 5.87, 95% CI 1.53-22.58, P = 0.01) as independent determinants. Late survival occurred in 175 patients, resulting in a survival rate of 86.2%, 67.3% and 33.3% at 1, 5 and 10 years, respectively (Fig. 2) . Independent determinants of survival were older age (HR 1.05, 95% CI 1.02-1.09, P < 0.001), left ventricular ejection fraction <30% (HR 2.71, 95% CI 1.57-4.68, P < 0.001) and chronic renal failure (HR 2.86, 95% CI 1.50-5.45, P = 0.002). The results of the multivariable model analysis of early and late clinical outcome are given in Table 3 .
Valve-related outcome
Thromboembolism and bleeding. After adjustment for death as a competing risk during follow-up, the freedom from thromboembolism and bleeding were 97.9% and 99.5% at 1 year, 97.4% and 99.5% at 5 years and 95.6% and 99.5% at 10 years, respectively.
Endocarditis. Seven patients developed bioprosthetic endocarditis, resulting in freedom from endocarditis of 99.1% and 96.5% at 5 and 10 years. Redo-AVR was performed successfully in 2 of the 3 patients, whereas 4 patients without obvious prosthesis dysfunction were treated conservatively with antibiotics.
Reoperation. Reoperation for all cardiac causes was required in 38 patients, 23 of which were performed for non-valve-related issues including pacemaker (n = 18) or internal defibrillator (n = 1) implantation, repeat surgical (n = 1) or transcatheter (n = 1) myocardial revascularization and late mitral valve repair (n = 1). Aortic valve-related reoperation yielded surgical redo-AVR in 11 patients (including 2 patients with endocarditis) and transcatheter valve implantation in 4 patients for bioprosthetic degeneration. Structural valve degeneration. The actual freedom from SVD at 1, 5 and 10 years was 100%, 99.1% and 89.3%, respectively, whereas the freedom from valve reoperation for SVD was 100%, 99.1% and 93.1% for the same time intervals. Based on competing risk modelling, both end-points are shown graphically by the cumulative incidence estimation curves ( Fig. 3A and B) , demonstrating a cumulative incidence for SVD of 0%, 0.7% and 6.2% at 1, 5 and 10 years, respectively. Twenty-six events of SVD were identified by echocardiographic assessment or reoperation, taking into account 175 deaths as competing events during the observed follow-up period. Early accelerated SVD within the first 5 years after surgery was noted in 3 patients, all of whom required a redo operation. Reoperation for SVD was performed in 16 patients. The mode of valve failure was stenotic calcific degeneration in 7 patients, all of them having a size 21 or 23 valve. Interestingly, in 3 of them, the obstruction was initiated by creep stenosis at the level of at least 1 prosthetic strut. In 6 patients, the explanted prosthesis demonstrated cusp rupture in valve sizes 21 (n = 1), 23 (n = 3) and 27 (n = 2), respectively. A multivariable competing risk-proportional hazard analysis for SVD was not able to identify an independent risk factor for SVD, although age > _75 years at the time of AVR tended to be associated with a lower risk of SVD (HR 0.50, 95% CI 0.23-1.08, P = 0.08) (Fig. 4) . Specific analysis of SVD in relation to valverelated factors demonstrated no significant effect of valve size (valve sizes 23-29 vs 19-21: HR 0.96, 95% CI 0.32-2.93, P = 0.94) or of PPM (HR 1.95, 95% CI 0.58-6.56, P = 0.29) (Fig. 5A and B) .
DISCUSSION
The well-known Achilles heel of bioprostheses is their tendency for structural deterioration, limiting their durability and therefore their widespread use in patients with substantial life expectancy. Many efforts have been made to deal with this shortcoming by improving the haemodynamic valve design and the handling of the biological tissue, the goal being to mitigate the calcification process [6, 14] . The early models of the Mitroflow bioprosthesis were not pretreated with an antimineralization substance and have been implanted successfully in thousands of patients worldwide.
However, specific construction-related features and the lack of anticalcification treatment have been suggested as the main causes of unacceptable early, accelerated structural degeneration [3, 4, 15] . Alvarez et al. reported a freedom from SVD of 95% and 56% at 5 and 10 years, noting the first occurrence within the 4th year after AVR. The results were even worse when prosthesis degeneration was noted on echocardiography scans even before it became haemodynamically significant, resulting in a 10-year freedom from SVD of barely 34% [3] . In 617 patients with a mean age of 76 years, Senage et al. found a linearized rate of SVD of 1.66% per patient-year, resulting in a 5-year freedom from SVD of 92% for the whole cohort but only 80% and 94% for those with valve sizes 19 and 21. They also observed a negative impact of SVD on survival, because nearly half of the patients who developed SVD contributed to the overall valve-related mortality. Recently, Piccardo et al. mentioned a freedom from SVD of 77% and 56% at 10 and 15 years, identifying the use of size 19, severe PPM and an increased transprosthetic gradient at discharge as risk factors for SVD [16] . Our study revealed a superior 5-to 10-year outcome in terms of freedom from SVD, without any impact on valve size. Compared with the results from previous studies, the proportion of AVRs that were done with a small prosthesis was substantially lower. Whereas sizes 19 to 21 were used in only 19% of our cohort, they represented 42% to 64% of all implanted valves in the aforementioned reports. Although subtle discrepancies in population demographics within Europe may affect the distribution of the valve sizes used [17] , the gender distribution and body surface area in our series were nonetheless identical. These parameters subsequently resulted in a significantly higher percentage of patients presenting with significant PPM, i.e. 4% severe to 58% moderate PPM in the series of Piccardo et al. [16] and 24% severe PPM in the series of Senage et al. [4] , a factor that has been criticized previously [18] .
PPM is a well-recognized predictor of accelerated SVD, usually from stenotic degradation [6, 19] . The incidence of PPM in our series was low-only 11% showed moderate mismatch-in agreement with the low number of valve sizes 19 to 21, which are more likely to induce PPM. There are several ways to avoid PPM. The choice of valve can be guided by the preoperative calculation of the projected EOA, but this approach does not explain our results, because the Mitroflow prosthesis was used consecutively as the principal bioprosthesis for AVR during that period. Secondly, PPM is preventable if one uses aortic root enlarging techniques, but these may complicate the operation in frail elderly patients. We believe that the surgical implantation technique based on the consistent use of single interrupted sutures and the supra-annular placement of the prosthesis has favoured the upgrading of valve sizes. This argument is supported by an in vitro assessment of the influence of the suture technique on valve haemodynamics. Tasca et al. proved that the use of single interrupted sutures in comparison with the often-used noneverting mattress sutures with pledgets helped to optimize the performance of the bioprosthesis by affording a larger EOA [20] . Tabata et al. confirmed this finding in a clinical trial with Carpentier-Edwards valve sizes 19 and 21, advocating it as the preferred technique for AVR in patients with small aortic annuli [21] . On the other hand, manifest oversizing of the Mitroflow prosthesis is not recommended, since the height of the prosthesis may come into conflict with closure of the aortotomy, especially in patients with a small aortic root. In 3 patients, calcific SVD was observed at the strut transitioning the right and non-coronary regions and was probably avoidable by primary patch insertion during aortic closure. Moreover, the external position of the pericardial sheet exposes the prosthesis to superficial abrasion- related damage during suture tying, which has been shown to promote degeneration [5] .
The absence of antimineralization treatment is considered a major drawback of the first-generation Mitroflow models. Flameng et al. pointed out that, in addition to PPM, the lack of antimineralization treatment is an independent determinant of SVD, promoting calcific stenotic degeneration as well as cusp rupture [6] . This conclusion was made from a retrospective analysis of 648 patients undergoing AVR with a heterogeneous variety of bioprostheses, including stented and stentless, porcine and pericardial and treated and untreated substitutes. Hence, because tissue valve degeneration is known to be multifactorial [22] , the effect of absent anticalcification pretreatment should be interpreted cautiously, given that PPM occurred frequently in that study, which yielded only a minority of Mitroflow valves, while comprising the Labcor prosthesis, known to have a poor longterm outcome.
Our data compare favourably with those from other reports on long-term outcomes with the first-generation Mitroflow prosthesis. Regardless of the substantial use of small valve sizes (71% sizes 19-21), Yankah et al. found that patients >70 years had an actuarial 20-year freedom from SVD of 85%, for a survival of 32% and 6% at 10 and 20 years, respectively [1] . In a large study of 1516 implants, half of which were sizes 19-21, Minami et al. reported a 10-year survival rate of 24.5% and a 10-year freedom from SVD of 83%. They recommended the Mitroflow bioprosthesis for patients older than 75 years with a small aortic annulus [23] . Some recent reports that shared the same concern about the lack of anticalcification treatment confirmed an acceptable valve durability, with stable haemodynamic performance within the first 5 years when used in patients older than 70 years [24, 25] . In contrast, Nielsen et al. favoured the CE-Perimount prosthesis in comparison with the Mitroflow, by demonstrating a 10-year freedom from SVD of 99% vs 95%, particularly due to an increased reoperation rate for Mitroflow sizes 19-21 [26] . Because the benefit of anticalcification treatment on prosthesis durability may appear later, further follow-up of our series is mandatory, because the 10-year results with SVD seem to be inferior to those with the CE-Perimount, which is still considered the standard for longevity performance among bioprostheses [27, 28] . Meanwhile, an increased susceptibility to phospholipid infiltration has been shown [23] , and a phospholipid reduction pretreatment has been added to the Mitroflow DL-model, available for clinical use since 2012.
Limitations
In a retrospective study comprising only elderly patients, the estimation of the outcome of a valve product is commonly affected by interfering events like death. We have tried to deal with this limitation by applying appropriate statistical methods and by limiting the study population to the cohort with complete clinical follow-up data. Because a majority of our patients are referred to and followed in a regional care network, it is still conceivable that the real number of SVD is underestimated, because the completeness of the echocardiographic follow-up is inferior to the clinical one. However, we feel confident, given the referral liability, to consider the reoperation rate as a valid estimation for SVD after excluding the reoperation for endocarditis.
Another shortcoming relates to the incomplete knowledge regarding the causes of death during the follow-up period. This analysis encompasses many studies that investigated the durability of the bioprostheses, wherein verification of the exact cause of death is often incomplete in this elderly population, which is affected by many associated cardiac and non-cardiac diseases. Nonetheless, the 5-year results are statistically powered by enough individuals at risk to strengthen the conclusion that premature and accelerated SVD is not an issue in our experience with the untreated Mitroflow prosthesis.
CONCLUSION
The study demonstrates that the first-generation Mitroflow bioprosthesis offers an acceptable freedom from SVD and reoperation at 5 to 10 years when used for AVR in patients older than 75 years. Early degeneration, occurring within the first 5 years after the operation, mainly of small valves, was rarely observed. In comparison with other series, we were able to limit the use of small prostheses (sizes 19-21), which we postulate to be favoured by the implantation technique comprising single interrupted sutures and the consistent supra-annular positioning of the prosthesis. Hereby, the incidence of significant PPM was reduced to 11%, thereby minimizing its impact as a strong determinant of early SVD. Knowing that the development of SVD of an aortic bioprosthesis is often multifactorial-in particular when it occurs prematurely-this study may help to clarify the perspective on the use of untreated Mitroflow models by empowering the surgeon's responsibility to match the prosthesis to the patient rather than emphasizing the potential weakness of the used product such as the lack of anticalcification treatment.
